Cancer epigenetics and diagnostics

Section information

Section edited by Maria Berdasco, James Chim, Roderick Dashwood, Carmen Jerónimo, Eckart Meese, Arpad Patai and Ed Seto

The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression.  This section publishes original epigenetic research focused on epigenetic profiling and its clinical value for future diagnosis, prognosis and prediction of response to therapies (pharmacoepigenetics). 

Previous Page Page 1 of 5 Next Page
  1. Research

    LINE-1 is preferentially hypomethylated within adenomatous polyps in the presence of synchronous colorectal cancer

    Conventional tubular adenomas are frequently detected in patients undergoing average risk screening colonoscopy and are over-represented in patients who will develop colorectal cancer (CRC). Whether features o...

    Alice Chu Jiang, Lela Buckingham, William Barbanera, Amoah Yeboah Korang, Faraz Bishesari and Joshua Melson

    Clinical Epigenetics 2017 9:25

    Published on: 9 March 2017

  2. Research

    The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer

    Colorectal cancers (CRCs) undergo distinct genetic and epigenetic alterations. Expression of mutL homolog 1 (MLH1), a mismatch repair gene that corrects DNA replication errors, is lost in up to 15% of sporadic tu...

    Andrea J. Savio, Miralem Mrkonjic, Mathieu Lemire, Steven Gallinger, Julia A. Knight and Bharat Bapat

    Clinical Epigenetics 2017 9:26

    Published on: 9 March 2017

  3. Research

    Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens

    MiRNA expression markers are well characterized in colorectal cancer (CRC), but less is known about miRNA expression profiles in colorectal adenomas. Genome-wide miRNA and mRNA expression analyses were conduct...

    Zsófia Brigitta Nagy, Barnabás Wichmann, Alexandra Kalmár, Orsolya Galamb, Barbara Kinga Barták, Sándor Spisák, Zsolt Tulassay and Béla Molnár

    Clinical Epigenetics 2017 9:22

    Published on: 14 February 2017

  4. Research

    Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India

    Oral squamous cell carcinoma (OSCC) is one of the common malignancies in Southeast Asia. Epigenetic changes, mainly the altered DNA methylation, have been implicated in many cancers. Considering the varied env...

    Baidehi Basu, Joyeeta Chakraborty, Aditi Chandra, Atul Katarkar, Jadav Ritesh Kumar Baldevbhai, Debjit Dhar Chowdhury, Jay Gopal Ray, Keya Chaudhuri and Raghunath Chatterjee

    Clinical Epigenetics 2017 9:13

    Published on: 3 February 2017

  5. Research

    Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival

    Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the appl...

    John K. Wiencke, Devin C. Koestler, Lucas A. Salas, Joseph L. Wiemels, Ritu P. Roy, Helen M. Hansen, Terri Rice, Lucie S. McCoy, Paige M. Bracci, Annette M. Molinaro, Karl T. Kelsey, Margaret R. Wrensch and Brock C. Christensen

    Clinical Epigenetics 2017 9:10

    Published on: 2 February 2017

  6. Research

    PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma

    Molecular biomarkers assisting risk-group assignment and subsequent treatment stratification are urgently needed for patients with squamous cell cancer of the head and neck region (HNSCC). Aberrant methylation...

    Verena Sailer, Emily Eva Holmes, Heidrun Gevensleben, Diane Goltz, Freya Dröge, Alina Franzen, Jörn Dietrich, Glen Kristiansen, Friedrich Bootz, Andreas Schröck and Dimo Dietrich

    Clinical Epigenetics 2017 9:12

    Published on: 2 February 2017

  7. Research

    UroMark—a urinary biomarker assay for the detection of bladder cancer

    Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, ...

    Andrew Feber, Pawan Dhami, Liqin Dong, Patricia de Winter, Wei Shen Tan, Mónica Martínez-Fernández, Dirk S. Paul, Antony Hynes-Allen, Sheida Rezaee, Pratik Gurung, Simon Rodney, Ahmed Mehmood, Felipe Villacampa, Federico de la Rosa, Charles Jameson, Kar Keung Cheng…

    Clinical Epigenetics 2017 9:8

    Published on: 31 January 2017

  8. Research

    CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

    Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell-cell adhesion and metastasis. Its role in cancer is controversial because it has been described as being upregulated in colorec...

    Esperanza Martín-Sánchez, Saioa Mendaza, Ane Ulazia-Garmendia, Iñaki Monreal-Santesteban, Alicia Córdoba, Francisco Vicente-García, Idoia Blanco-Luquin, Susana De La Cruz, Ana Aramendia and David Guerrero-Setas

    Clinical Epigenetics 2017 9:7

    Published on: 24 January 2017

  9. Research

    Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

    Biliary tract carcinoma (BTC) is a fatal malignancy which aggressiveness contrasts sharply with its relatively mild and late clinical presentation. Novel molecular markers for early diagnosis and precise treat...

    V. Branchi, P. Schaefer, A. Semaan, A. Kania, P. Lingohr, J. C. Kalff, N. Schäfer, G. Kristiansen, D. Dietrich and H. Matthaei

    Clinical Epigenetics 2016 8:133

    Published on: 12 December 2016

  10. Research

    Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance

    Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in western countries, characterized by a heterogeneous clinical course. Although genetic studies have identified chromosomal aberr...

    Michaël Van Damme, Emerence Crompot, Nathalie Meuleman, Marie Maerevoet, Philippe Mineur, Dominique Bron, Laurence Lagneaux and Basile Stamatopoulos

    Clinical Epigenetics 2016 8:132

    Published on: 7 December 2016

  11. Research

    Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer

    Long noncoding RNAs (lncRNAs) are more than 200 nucleotides in length and lack transcriptional ability. The biological function of lncRNAs in oral squamous cell carcinoma (OSCC) remains unclear. The aim of thi...

    Cheng-Mei Yang, Tsung-Han Wang, Hung-Chih Chen, Sung-Chou Li, Ming-Chien Lee, Huei-Han Liou, Pei-Feng Liu, Yu-Kai Tseng, Yow-Ling Shiue, Luo-Ping Ger and Kuo-Wang Tsai

    Clinical Epigenetics 2016 8:129

    Published on: 26 November 2016

  12. Research

    Smoking-associated DNA methylation markers predict lung cancer incidence

    Newly established blood DNA methylation markers that are strongly associated with smoking might open new avenues for lung cancer (LC) screening. We aimed to assess the performance of the top hits from previous...

    Yan Zhang, Magdeldin Elgizouli, Ben Schöttker, Bernd Holleczek, Alexandra Nieters and Hermann Brenner

    Clinical Epigenetics 2016 8:127

    Published on: 25 November 2016

  13. Review

    Genome-wide epigenomic profiling for biomarker discovery

    A myriad of diseases is caused or characterized by alteration of epigenetic patterns, including changes in DNA methylation, post-translational histone modifications, or chromatin structure. These changes of th...

    René A. M. Dirks, Hendrik G. Stunnenberg and Hendrik Marks

    Clinical Epigenetics 2016 8:122

    Published on: 21 November 2016

  14. Research

    Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma

    Pancreatic cancer has a 5-year survival rate of only 5–7%. Difficulties in detecting pancreatic cancer at early stages results in the high mortality and substantiates the need for additional diagnostic tools. ...

    Stine Dam Henriksen, Poul Henning Madsen, Anders Christian Larsen, Martin Berg Johansen, Asbjørn Mohr Drewes, Inge Søkilde Pedersen, Henrik Krarup and Ole Thorlacius-Ussing

    Clinical Epigenetics 2016 8:117

    Published on: 16 November 2016

  15. Research

    Global DNA methylation patterns in Barrett’s esophagus, dysplastic Barrett’s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use

    The risk of developing Barrett’s esophagus (BE) and/or esophageal adenocarcinoma (EAC) is associated with specific demographic and behavioral factors, including gender, obesity/elevated body mass index (BMI), ...

    Andrew M. Kaz, Chao-Jen Wong, Vinay Varadan, Joseph E. Willis, Amitabh Chak and William M. Grady

    Clinical Epigenetics 2016 8:111

    Published on: 27 October 2016

    The Erratum to this article has been published in Clinical Epigenetics 2017 9:23

Previous Page Page 1 of 5 Next Page